SCHEMBL7339341

SCHEMBL7339341

CCCCCCNCC(N)=O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.67
MAOB P27338 2/20 0.67
EPHX1 P07099 6/20 0.50
ALDH1A1 P00352 1/20 0.50
TSHR P16473 1/20 0.50
MEN1 O00255 1/20 0.48
FAAH O00519 1/20 0.48
TP53 P04637 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C19 P33261 1/20 0.48
SOAT1 P35610 1/20 0.48
KMT2A Q03164 1/20 0.48
S1PR2 O95136 5/20 0.47
S1PR4 O95977 5/20 0.47
S1PR1 P21453 5/20 0.47
S1PR3 Q99500 5/20 0.47
S1PR5 Q9H228 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7338476 1.00 MAOA (0.67) MAOAMAOBEPHX1ALDH1A1TSHR
SCHEMBL28278160 1.00 MAOA (0.67) MAOAMAOBEPHX1ALDH1A1TSHR
SCHEMBL28278157 1.00 MAOA (0.67) MAOAMAOBEPHX1ALDH1A1TSHR
SCHEMBL19745716 1.00 MAOA (0.67) MAOAMAOBEPHX1ALDH1A1TSHR
SCHEMBL7340676 1.00 MAOA (0.67) MAOAMAOBEPHX1ALDH1A1TSHR
SCHEMBL7348161 1.00 MAOA (0.67) MAOAMAOBEPHX1ALDH1A1TSHR
SCHEMBL7377007 1.00 MAOA (0.67) MAOAMAOBEPHX1ALDH1A1TSHR
SCHEMBL7344423 1.00 MAOA (0.67) MAOAMAOBEPHX1ALDH1A1TSHR
SCHEMBL31404236 0.98 MAOA (0.64) MAOAMAOBEPHX1ALDH1A1TSHR
Milacemide SCHEMBL194513 0.98 MAOA (0.63) MAOAMAOBEPHX1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3275861-A1 TETRACYCLINE COMPOUNDS Tetraphase Pharmaceuticals, Inc. (US) 2018-01-31 EP disclosed
US-20170334841-A1 TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS, INC. 2017-11-23 US disclosed
EP-2470500-B1 TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS INC (US) 2017-10-04 EP disclosed
US-9624166-B2 Tetracycline compounds TETRAPHASE PHARMACEUTICALS, INC. (US) 2017-04-18 US disclosed
US-20120208788-A1 Tetracycline Compounds TETRAPHASE PHARMACEUTICALS, INC. 2012-08-16 US disclosed
US-4639468-A Derivatives of glycinamide, their preparation and their use CONTINENTAL PHARMA INC. (BE) 1987-01-27 US disclosed
US-4088500-A AMIDE-ENDCAPPED HYDROPHILIC ALKYLENE OXIDE PREPOLYMER, ACID ACTIVATED CROSSLINKING AGENT WATER, FILLER, CATALYST MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1978-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334841-A1 TETRACYCLINE COMPOUNDS TUBB, TUBA1A, TUBA1C MAOA 1967/4885MAOB 1699/4885EPHX1 4485/4885
US-20120208788-A1 Tetracycline Compounds TUBA1A, TUBA1C, TUBB1 MAOA 2165/4885MAOB 2000/4885EPHX1 4330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.